Glycodelin (PAEP) gene promoter polymorphism rs760140467 C>T is associated with recurrent pregnancy loss by Sharif, Fadel A.








International Journal of Medical Research & 





Glycodelin (PAEP) gene promoter polymorphism rs760140467 C>T is 
associated with recurrent pregnancy loss 
 
Fadel A. Sharif  
 
Department of Medical Laboratory Sciences, Faculty of Health Sciences 
Islamic University of Gaza, Palestine 





In the absence of confirmed causes for around 50% of recurrent pregnancy loss (RPL) cases this study was 
conducted in order to evaluate the relationship between PAEP gene single nucleotide polymorphism (SNP) 
rs760140467 C>T and recurrent pregnancy loss (RPL) in Palestinian women. A retrospective case-control study 
was carried out during the period (August 2015 to April 2016). A total of 200 females, 100 RPL patients and 100 
control women without previous history of RPL were included in the study. PAEP (rs760140467 C>T) 
polymorphism was tested by PCR-RFLP. Statistically significant difference existed between RPL cases and co trols 
in terms of the genotypic and allelic distribution f the tested polymorphism. PAEP "T/C" genotype and "T" allele 
were significantly higher in the RPL group.  The study showed, for the first time, that the "C/T" genotype and the "T' 
allele of the tested polymorphism are strongly associated with RPL in the investigated population. This finding may 
lead to improved therapeutic approaches for those RPL cases. 
 





Glycodelin, the product of PAEP (Progestagen-Associated Endometrial Protein) gene on chromosome 9q34.3, is 
secreted by the uterine endometrium under progesterone induction, and is the most abundant progesterone-regulated 
secretory glycoprotein of the uterus at the time of implantation and early pregnancy. Glycodelin is inhibitory to the 
activity of T, B, NK cells and monocytes [1-3] and significantly contributes to immunomodulation towards fetal 
tolerance [4].  Importantly, subnormal levels of glycodelin  correlates with recurrent miscarriage [5].
 
Several investigators have assessed the possible associ tion between RPL and immune tolerance-related genes' 
SNPs, including cytokines e.g., IL-10 [6], receptors e.g., CTLA-4 [7] and transcription factors e.g., FOXP3 [8]. 
Results of those studies suggest that such SNPs may confer susceptibility to RPL by modulating the immune system 
at the materno–fetal interface.  
 
Due to its important immuno-modulatory role during early phases of pregnancy, this study was undertaken in order 
to test, for the first time, whether PAEP promoter "rs760140467 C/T" SNP is associated with RPL. The reason 
behind selecting this particular SNP is that it is located in a plausible progesterone receptor binding motif. 
 
MATERIAL AND METHODS 
 
Selection of PAEP promoter SNP rs760140467 C>T 
The PAEP gene promoter sequence was first retrieved from the promoter database (https://cb.utdallas.edu/cgi-
bin/TRED/tred.cgi?process=searchTF GeneForm) and then searched for progesterone receptor (PR) binding motifs 
[9]. The two PR binding sites found were then searched for single nucleotide variation by consulting Ensembl 
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database (http://asia.ensembl.org/ Homo_sapiens/Info/Index), and the SNP rs760140467 (-468 C>T) was thus 
selected for genotyping .  
 
Study population  
The study was conducted on 100 Palestinian women, 18–35 years old, who had at least two RPLs ≤20 weeks of 
gestation. Age and ethnicity matched 100 women with at least two live births and without a previous hitory of 
abortion or pregnancy-associated complications served as the control group.  
 
Ethical Considerations  
Informed consent was obtained from all participants and the study procedure was approved by the local ethics 
committee.  
 
DNA extraction  
The DNA was isolated from whole blood samples using Wizard DNA extraction kit (Promega, USA) as described 
by the manufacturer. The isolated DNA was stored at -20°C until analysis of the polymorphism. 
 
Analysis of PAEP gene SNP by rs76014067 T>C  PCR-RFLP  
The PAEP SNP rs76014067 T>C was genotyped using PCR-RFLP protocol. The primers were designed using 
online Primer3 software (http://primer3.ut.ee/) based on the genomic sequence  deposited in the NCBI gene bank 
and the SNP sequence was retrieved from NCBI-SNP database. 
 
Then restriction enzyme "BciVI" required for the PCR-RFLP identification of the SNP alleles was  selected from 
new England Biolabs web site (http://nc2.neb.com/NEBcutter2/). The PCR primers, restriction enzyme digestion 
results and interpretation were done as depicted in Table-1. 
 
The PCR reaction was carried out in a total volume of 20 µL, with 10 µL Taq PCR Master mix (Promega, USA), 
2µL (10pmol) of each primer, 4µL nuclease-free water and 2µL (50ng) genomic DNA. The PCR protocol was 
performed with an initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation for 1 min at 94°C, 
annealing for 45 sec at 57°C and extension for 50 sec at 72°C. Final extension was carried out for 5 min at 72°C. 
The PCR 182 base pairs (bp) product size was confirmed with electrophoresis in ethidium bromide-stained 2% 
agarose gel .  
 
A 10µL aliquot of the PCR product (182 bp) was digested with "BciVI" restriction enzyme (NEB, UK) according to 
the manufacturer instructions and the restriction digest was separated in ethidium bromide-stained 2% agarose gel. 
 
Table 1: The PCR-RFLP requirements for genotyping SNP rs76014067 T>C. 
 
Interpretation Restriction enzyme PCR product size PCR primers 
"C" allele : 182 bp (uncut) 
"T" allele : 93 + 89 bp 
 BciVI 182 bp  F: CTCCCATTTCCACCCAGTCT 
R: CACAGACATCATGCCAGTGG 
 
Statistical analysis  
The genotypes and alleles frequencies in RPL patients a d the controls were analyzed by standard odds ratio (OR) 




Genotype and allele distribution of the investigated polymorphism in RPL subjects and controls. 
The genotype and allele frequencies of the study population are shown in (Table-2). Statistical analyses revealed that 
the "C/T" genotype and the "T" allele of rs760140467 polymorphism existed in significantly higher frequencies in 
the RPL cases.  
 
Table 2. The frequencies of SNP rs760140467 genotypes and alleles in RPL and control groups 
 
Genotype or allele RPL group Control group OR (95% CI) P value 






C/T 26 10 
T/T - - 
"C" allele 174 190 
2.84 (1.33-6.06) 0.0070* 
"T" allele 26 10 
* Statistically significant 
 
 





Successful implantation and maintenance of pregnancy relies on the immune tolerance imposed by the mother 
against her semi-allogeneic fetus. This immune tolerance is largely dictated by the structure of the 
microenvironment at the feto-maternal interface.  Endometrial glycodelin, the product of PAEP gene, is a major 
glycoprotein component of this microenvironment. Glycodelin facilitates implantation and maintains pregnancy by 
inhibiting the immune response [10].  
 
In the present work, we have for the first time demonstrated an association between RPL and the PAEP gene 
promoter SNP "rs760140467 C>T". We found that RPL risk in carriers of the "T" allele and the "C/T" genotype is 
higher than in women harboring the "C" allele or the "C/C" genotype (ORs = 2.84 and 3.16, respectively). The 
association between this polymorphism and RPL could be ue to lower glycodelin expression of the T-allele, as this 
polymorphism is located within a progesterone receptor binding site. Suppression of serum and endometrial 
glycodelin levels has been shown to impair the preimplantation environment and to increase the rate of arly 
pregnancy loss [11]. 
 
The association of this immune tolerance-related gene polymorphism may be useful for testing its relevance in other 
populations with different ethnic backgrounds and may assist in identifying treatments such as glycodelin 
administration or enhancing glycodelin gene expression. Meanwhile, research is ongoing to determine th
importance of this polymorphism on a larger sample and to correlate the "T" allele with the level of glycodelin in 
pregnant women. 
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